Encompass Health Corp (EHC) stock analysis
Close on Nov 10, 2026Market cap $14.06BP/E 23.2Yield 0.51%
StockData Score
Prices as of Nov 11, 2026How the score works
Solid16 of 30 checks passed
Encompass Health passes 16 of the 30 checks behind our score; 3 could not be run for lack of data and count as not passed. Each dot in the shape is one check — hover it for the numbers.
- Valuation
- 1/6
- Growth
- 4/6
- Past performance
- 5/6
- Financial health
- 3/6
- Dividend
- 3/6
What stands out
Return on equity over 15%
Return on equity was 25.5% over the last twelve months and averaged 22.8% over five years.
Earnings grew over 5 years
Net income grew 14.8% a year on average over the last five fiscal years.
Revenue growing 10%+ a year
Revenue grew 10.9% a year over the last three fiscal years.
EPS growing 10%+ a year
Diluted EPS grew 27.1% a year over the last three fiscal years.
What to watch
Margin of safety under 20%
The price is 14.0% above fair value, so there is no margin of safety.
Trading above fair value
The share price of $142.51 is above our fair value estimate of $125.04.
High debt
Debt is 101% of shareholders' equity, above the 40% we consider low.
Bankruptcy risk in the grey zone
The Altman Z-score is 2.97; above 3 is the safe zone and below 1.8 the distress zone.
Valuation1/6
P/E above its 5-year median
Encompass Health's P/E of 23.2 is above its own 5-year median of 21.4.
P/E below the industry
Encompass Health's P/E of 23.2 is below the Health Services median of 23.9.
EV/EBITDA above its 5-year median
Encompass Health's EV/EBITDA of 11.6 is above its 5-year median of 11.2.
P/B above the industry
Encompass Health's price-to-book of 5.41 is above the Health Services median of 3.52.
Trading above fair value
The share price of $142.51 is above our fair value estimate of $125.04.
Margin of safety under 20%
The price is 14.0% above fair value, so there is no margin of safety.
Growth4/6
Revenue growing 10%+ a year
Revenue grew 10.9% a year over the last three fiscal years.
EPS growing 10%+ a year
Diluted EPS grew 27.1% a year over the last three fiscal years.
Earnings growth accelerating
Net income grew 18.8% over the last twelve months, against a 5-year average of 14.8% a year.
Growing faster than the industry
Revenue grew 9.5% over the last twelve months; the Health Services median is 4.0%.
Guidance lowered
Encompass Health lowered its 2026 Amortization of debt-related items outlook on Aug 5, 2026.
Gross margin trend
This company does not report gross profit.
Past performance5/6
Return on equity over 15%
Return on equity was 25.5% over the last twelve months and averaged 22.8% over five years.
Return on invested capital
Needs operating income and invested capital.
Return on equity above the industry
Encompass Health's return on equity of 25.5% is above the Health Services median of 4.6%.
Earnings grew over 5 years
Net income grew 14.8% a year on average over the last five fiscal years.
Net margin above its 5-year average
Net margin was 10.0% over the last twelve months, against a 5-year average of 8.4%.
Net margin above the industry
Encompass Health's net margin of 10.0% is above the Health Services median of -2.6%.
Financial health3/6
High debt
Debt is 101% of shareholders' equity, above the 40% we consider low.
Debt falling against equity
Debt to equity fell from 207% five years ago to 101%.
Debt covered by cash flow
Operating cash flow over the last twelve months equals 46.0% of total debt.
Interest coverage
Interest expense is not reported separately.
Short-term assets cover short-term debts
Current assets are 1.19 times current liabilities.
Bankruptcy risk in the grey zone
The Altman Z-score is 2.97; above 3 is the safe zone and below 1.8 the distress zone.
Dividend3/6
Pays a dividend
Encompass Health paid dividends worth 0.5% of the share price over the last twelve months.
Yield below Treasuries
The 0.5% yield is below the 4.4% on a 1-year Treasury.
Yield below the top quarter
The top quarter of US dividend payers yield 3.8% or more; Encompass Health yields 0.5%.
Dividend was cut
The dividend per share fell by more than 10% at least once in the last 10 fiscal years.
Covered by earnings
Dividends take 12.1% of net income.
Covered by free cash flow
Dividends take 18.2% of free cash flow.
Fair value
How we estimate itOur estimate per share
$125.04
The share price is 14% above this estimate.
| Method | Multiple used | Own 5Y median | Industry median | Value per share | Weight |
|---|---|---|---|---|---|
| P/E | 22.7× | 21.4× | 23.9× | $139.15 | 44% |
| EV/EBITDA | 9.9× | 11.2× | 8.6× | $125.30 | 39% |
| Earnings power | 8.3% cost of equity | – | – | $86.78 | 17% |
| Fair value | $125.04 | 100% | |||
Valuation over time
Using the earnings and balance sheet published at each date, not today's.
- P/E at month end
- Own 5-year median 21.4
- Health Services median 23.9
An estimate from reported numbers and market multiples, not a price target or investment advice. It can be far off for companies whose profits are about to change sharply.
Market risk
From the past year of daily prices.
Liquidity
Low risk
- Average value traded per day
- $149.96M
- Value traded per 1% price move
- $108.46M
Downside
Low risk
- Typical loss in a bad month
- 11.4%
- Volatility (annualized)
- 31%
- Sharpe ratio, 1 year
- 0.63
- Beta to the S&P 500 (5Y)
- 0.68
Typical bad-month loss, week by week
Margins
Share of revenue, fiscal years 2011 to 2025
Operating margin
Net margin
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +10.5% | +10.9% | +10.7% | – | |
| Net income | +24.2% | +27.8% | +14.8% | +12.0% | |
| EPS, diluted | +24.2% | +27.1% | +14.2% | +11.2% | |
| Free cash flow | +21.9% | +53.4% | +7.1% | +1.6% | |
| Dividend per share | +12.5% | -5.8% | -8.5% | -2.0% |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | 36.8% | 19.3% | 25.1% | |
| Return on assets | 5.3% | 4.5% | 8.3% | |
| Current ratio | 1.38 | 1.32 | 1.08 | |
| Debt to equity | 4.10 | 2.07 | 1.02 | |
| Net debt to EBITDA | 3.91× | 4.05× | – | |
| Interest coverage | 3.4× | 3.1× | – | |
| Capex to revenue | 4.9% | 11.0% | 12.4% | |
| Diluted shares | 100M | 100M | 102M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Encompass Health generated $4.45B from operations and spent $3.69B on capital expenditure, dividends and share buybacks. 84% of that went back into the business.
DuPont analysis
Return on equity split into margin, efficiency and leverage
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | 9.5% | 0.87× | 3.02× | 25.1% |
| FY2024 | 8.5% | 0.85× | 3.40× | 24.5% |
| FY2023 | 7.3% | 0.82× | 3.97× | 23.8% |
| FY2022 | 6.2% | 0.70× | 3.88× | 16.8% |
| FY2021 | 10.3% | 0.60× | 3.80× | 23.6% |
| FY2020 | 8.0% | 0.57× | 4.26× | 19.3% |
| FY2019 | 7.8% | 0.82× | 4.28× | 27.3% |
| FY2018 | 6.8% | 0.85× | 4.13× | 24.1% |
| FY2017 | 6.9% | 0.82× | 5.06× | 28.7% |
| FY2016 | 6.8% | 0.78× | 6.89× | 36.8% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
- ProfitableNet income above zero$566.20M
- Cash generatingOperating cash flow above zero$1.18B
- Return on assets improvedROA up on the prior year7.5% → 8.7%
- Earnings backed by cashOperating cash flow above net income$1.18B vs $566.20M
- Less leverageLong-term debt to assets fell36.1% → 34.5%
- Better liquidityCurrent ratio rose1.05 → 1.08
- No dilutionShare count did not rise102M → 102M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose0.88 → 0.91
See a number that looks wrong?